Skip to main content

Pharmacogenomic panel testing for personalized supportive oncology

In brief

Pharmacogenomic testing changed supportive cancer prescriptions for 14% of patients

In this single-arm trial, testing led to a drug change or other guided intervention in 9 of 66 patients, mostly involving opioids or antidepressants. Drug-gene interactions were found in about one-third at baseline and final visits, while electronic alerts fired for 18% of evaluable patients; whether testing improves symptoms or other outcomes remains unknown.

Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (Q1)
Published
17 November 2026
Study design
Non-randomized / quasi-experimental trial
Evidence level
Level 2, Moderate (CEBM 2b)
Authors
D Grace Nguyen, Sarah A Morris, Danielle M Boselli, Alicia Hamilton, Mathew Smith, Nury Steuerwald, et al.
PMID
43049798
DOI
10.1007/s00520-026-11489-x

Why clinicians should know about it

  • Picked for Genetics (clinical) (top studies of the week, 22 November 2026): Clinical pharmacogenomic testing informs prescribing and drug-gene interventions

Abstract

PURPOSE: Drug response for cancer symptom management is variable. The purpose of this trial is to study the impact of multigene pharmacogenomic (PGx) testing on drug prescribing in supportive oncology. METHODS: This is a single-arm prospective trial of adults with cancer referred to the supportive oncology clinic with Edmonton Symptom Assessment System pain ≥ 4, depression ≥ 3, or requiring antidepressant modification. Patients were genotyped for variants in CYP3A4, CYP3A5, CYP2D6, CYP2C9, CYP2C19, CYP2B6, COMT, OPRM1, SLC6A4, and HTR2A, and assessed every 4 weeks up to a maximum of 16 weeks. Primary endpoint was the proportion of patients with ≥ 1 PGx-guided intervention. Secondary endpoints included the type/frequency of drug-gene interactions (DGIs) at baseline and final visits, and the type/frequency of interruptive PGx alerts in the electronic health record (EHR). RESULTS: 70 patients were genotyped (54% female, 67% White, 33% Black, median age 59). Gynecologic (21%), breast (14%), and hematologic (14%) cancers were most common, and 64% had stage III or IV disease. 50% and 59% carried a CYP2D6 or CYP2C19 non-normal metabolizer phenotype, respectively. Of 66 evaluable patients, 9 (14%, 95% CI 7-24%) had a PGx-guided intervention, mostly for opioids and antidepressants. At baseline and final visits, 25 (n = 23; 35%) and 22 (n = 21; 32%) DGIs, respectively, were present. There were 26 interruptive alerts triggered for 10 (18%) of 56 patients evaluable for PGx alerts, mostly for CYP2C19-proton pump inhibitors (PPIs) and CYP2C19/CYP2B6-antidepressants. CONCLUSION: DGIs, mostly for opioids, antidepressants, and PPIs, were common and PGx-guided interventions occurred in a minority of patients. Interruptive alerts were frequent and prompted PGx-guided interventions in most patients with actionable interactions, highlighting the opportunity to optimize EHR-based clinical decision support.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.